These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20504164)

  • 1. Instantaneous inhibitory potential and inhibitory quotient show a modest association with virologic outcome: is either a useful surrogate for clinical drug efficacy?
    MacArthur RD
    Clin Infect Dis; 2010 Jul; 51(1):99-100. PubMed ID: 20504164
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surrogate endpoints in clinical studies exemplified by HIV infection].
    Furrer H
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the inhibitory quotient in HIV therapy.
    Hoefnagel JG; Koopmans PP; Burger DM; Schuurman R; Galama JM
    Antivir Ther; 2005; 10(8):879-92. PubMed ID: 16430193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV suppression and risk of drug resistance mutations.
    Phillips AN; Loveday C; Johnson MA
    AIDS; 1998 Oct; 12(14):1930. PubMed ID: 9792396
    [No Abstract]   [Full Text] [Related]  

  • 7. Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.
    Henrich TJ; Ribaudo HJ; Kuritzkes DR
    Clin Infect Dis; 2010 Jul; 51(1):93-8. PubMed ID: 20504163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structured treatment interruptions--new findings.
    Benson CA
    Top HIV Med; 2006; 14(3):107-11. PubMed ID: 16946455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 and HAART: a time to cure, a time to kill.
    Saag MS; Kilby JM
    Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
    [No Abstract]   [Full Text] [Related]  

  • 11. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral load testing in resource-limited settings.
    Schooley RT
    Clin Infect Dis; 2007 Jan; 44(1):139-40. PubMed ID: 17143830
    [No Abstract]   [Full Text] [Related]  

  • 14. Principles of current adult HIV pharmacotherapy.
    Landor M
    Ann Allergy Asthma Immunol; 1998 May; 80(5):363-7; quiz 367-8. PubMed ID: 9609603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 in the female genital tract and the effect of antiretroviral therapy.
    Cu Uvin S; Caliendo AM; Reinert SE; Mayer KH; Flanigan TP; Carpenter CC
    AIDS; 1998 May; 12(7):826-7. PubMed ID: 9619822
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.
    Nicastri E; Chiesi A; Angeletti C; Sarmati L; Palmisano L; Geraci A; Andreoni M; Vella S;
    J Med Virol; 2005 Jun; 76(2):153-60. PubMed ID: 15834865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antiretroviral therapy on plasma HIV RNA.
    Saag MS
    J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 20. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
    Hill A; Miralles D; Vangeneugden T; Lefebvre E
    AIDS; 2007 Jul; 21(12):1651-3. PubMed ID: 17630565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.